SynthesisInflammopharmacology2025
Exploring the efficacy of plant-based nutraceuticals in managing diabetic neuropathy.
Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes-induced peripheral neuropathy is one of the most common complications in patients with diabetes. Plant-derived natural products have been tested in animal models as agents to treat this complex condition. Therefore, this study aimed to examine the therapeutic potential of plant-based nutraceuticals used for managing diabetic neuropathy in rat models using a systematic literature review approach. The literature review was performed in November 2023 on two databases, PubMed and Scopus. Nerve conduction velocity and pain-related behaviors were considered primary outcome measures. For meta-analysis, a random effect model was selected with a mean difference at 95% confidence intervals to estimate the effect of plant-based nutraceuticals on the primary outcome measures. Eighteen studies were included in the meta-analysis, with results indicating that plant extracts or isolated compounds significantly increased nerve conduction velocity and thermal and mechanical paw withdrawal latencies. Different mechanisms of action to reduce neuropathy symptoms have been proposed in these studies including a reduction in inflammatory cytokines and oxidative stress markers. This study suggests that plant-based therapies are effective in the management of diabetes-induced peripheral neuropathy. However, more studies are required with a standard experimental design and reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.